Vator Securities advises ZignSec on 59 MSEK Rights Issue
ZignSec AB (publ) is a RegTech company, providing an integrated end-to-end KYC, KYB compliance platform, facilitating seamless customer onboarding and monitoring, so clients can confidently expand operations internationally while remaining compliant.
Currently ZignSec has more than 500 customers spread across a range of industries where identification is essential, with the greatest concentration in financial services and other regulated activities.Read More
Vator Securities advises Moberg Pharma on 121 MSEK Rights Issue
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis.
Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the Company’s goal is to receive its first market approval and launch MOB-015 in 2023.Read More
Vator Securities advises ExpreS2ion Biotechnologies on 73 MSEK Rights Issue
ExpreS2ion Biotech is a biotechnology company that develops vaccines based on complex proteins targeting infectious diseases and cancer. The company develops a pipeline of preventive and therapeutic vaccine products while generating revenue by outlicensing the company’s ExpreS2 platform.
The lead candidate targeting COVID-19 is outlicensed to Bavarian Nordic, with positive phase II data announced in February 2022 and phase III expected to be initiated during H1 2022.Read More
Vator Securities advises S2Medical on 21 MSEK Rights Issue
S2Medical AB is a company founded in 2013 based in Linköping that develops and sells wound healing products with a focus on burns and chronic wounds.
The company aims to offer a holistic concept in wound healing with products in debridement (cleaning of wounds), granulation (construction of blood vessel-rich tissue) and re-epithelialization (outer tissue growth).Read More
Vator Securities advises Rebelle on 200 MSEK IPO
Rebelle operates the European online marketplace Rebelle.com for selling and buying luxury second hand fashion items and accessories.
Rebelle is offering products from the world’s most sought after fashion brands, such as Louis Vuitton, Chanel, Gucci, Hermès and Prada while increasing customers awareness of sustainability and circularity within the fashion industry. Rebelle offers more than 200,000 products to, and listed by, customers throughout Europe with focus on the EU.Read More
Vator Securities advises Cyxone on 67 MSEK Rights Issue
Cyxone is a Swedish clinical stage medicine platform company focused on developing and advancing novel solutions for patients suffering from severe autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS).
“The proceeds from the Rights Issue will enable us to implement the next important steps in the development of Cyxone’s new treatment for rheumatoid arthritis (RA). We have a solid and well-structured plan for delivering value creation to our shareholders and to patients world-wide, and our experienced team are now looking forward to take the Company to the next level,” comments Tara Heitner, CEO, Cyxone.Read More
Vator Securities advises Idogen on 50 MSEK Rights Issue
Idogen is a Swedish biotechnology company that develops tolerogenic cell therapies with the aim of treating unwanted activation of the immune system.
The Company conducts three development areas with a focus on treating patients with unwanted activation of the immune system. For the most advanced candidate, IDO 8, intended for patients with severe hemophilia and with antibodies against their treatment, the company’s intention is to submit an application for approval to start a clinical phase I/IIa study in December 2021.Read More
Vator Securities advises Precise Biometrics on 23 MSEK Directed Share Issue
Precise Biometrics is a global identification software provider, offering products with a range of application for identification in a convenient and secure way. Precise offers products with various applications that enable individuals to identify themselves by using biometrics.
Precise intends to use the net proceeds from the directed issue to finance part of the company’s acquisition of EastCoast Solutions.Read More